https://067527.iqanda-cme.com/ 2025-08-16T01:04:55+0000 weekly 1 https://067527.iqanda-cme.com/about-ptcl-hematology-oncology-intelligence-zone 2025-08-25T23:15:23+0000 weekly 0.8 https://067527.iqanda-cme.com/ptcl-hematology-oncology-intelligence-zone 2025-09-10T02:12:51+0000 weekly 0.8 https://067527.iqanda-cme.com/resources-and-trials-in-ptcl-therapy 2025-08-21T21:27:43+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/in-light-of-the-adoption-of-duvelisib-for-r/r-patients-with-ptcl-fth-disease-how-do-you-view-the-current-and-future-clinical-approaches-that-might-deploy-this-treatment-in-this-patient-population 2025-09-11T17:06:55+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/based-on-your-real-world-experience-with-duvelisib-in-ptcl-tfh-what-role-do-you-see-for-this-agent 2025-09-03T03:08:36+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/trials-such-as-primo-have-reported-on-multiple-dosing-regimens-of-duvelisib-how-do-you-dose-duvelisib-in-the-r/r-setting-and-when-used-for-bridging-in-patients-awaiting-allograft-stem-cell-transplantation 2025-09-03T03:10:35+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/given-duvelisib-s-strong-response-and-survival-signals-in-ptcl-tfh-from-the-primo-study-how-did-these-findings-influence-the-terzo-trial-s-design-dosing-strategy-and-outcome-goals 2025-09-03T02:59:12+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/how-do-you-use-the-nccn-guidelines-and-specifically-their-specific-recommendations-endorsing-duvelisib-as-both-monotherapy-and-in-combination-with-romidepsin 2025-09-03T03:10:21+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/once-the-diagnosis-of-ptcl-tfh-lymphoma-is-established-in-a-patient-what-does-the-treatment-pathway-and-standard-of-care-protocol-look-like-for-persons-with-this-variant 2025-09-03T03:04:41+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/as-duvelisib-and-other-novel-agents-are-used-in-r/r-ptcl-tfh-what-biological-features-of-ptcl-support-targeting-pi3k-and-hdac-pathways-and-why-do-these-mechanisms-make-sense-therapeutically 2025-09-11T17:02:58+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/what-current-ongoing-studies-are-evaluating-the-role-of-duvelisib-as-part-of-a-first-line-combinatorial-regimen-that-would-be-used-along-with-chop-upon-confirmation-of-ptcl-tfh 2025-09-03T03:09:57+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/how-did-duvelisib-a-delta-gamma-pi3k-inhibitor-with-known-activity-in-hematological-malignancies-emerge-as-an-important-therapy-of-interest-for-ptcl-tfh 2025-09-03T03:04:54+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/what-is-the-adverse-event-profile-for-duvelisib-in-your-clinical-experience-and-how-do-you-manage-and-mitigate-these-side-effects-in-the-real-world-management-of-patients-with-r/r-ptcl-tfh 2025-09-03T03:09:41+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/duvelisib-is-being-deployed-for-the-treatment-of-r/r-ptcl-tfh-as-well-as-for-bridging-patients-who-are-awaiting-allograft-stem-cell-transplant-can-you-discuss-similarities-and-differences-between-u-s-and-european-approaches 2025-09-03T02:59:24+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/how-did-primo-s-strong-duvelisib-results-in-ptcl-tfh-better-response-survival-impact-terzo-trial-design-dosing-strategy-and-outcome-goals 2025-09-03T03:07:52+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/given-the-heterogeneity-of-ptcl-in-particular-the-differential-outcomes-based-on-subtype-classification-what-is-the-evidence-and-rationale-for-moving-away-from-a-one-treatment-fits-all-approach 2025-09-11T17:00:54+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/can-you-share-how-you-made-the-therapeutic-and-evidence-based-handshake-between-the-dual-delta-gamma-pi3k-inhibitor-duvelisib-and-subsequent-evaluation-in-patients-with-ptcl-tfh-and-what-you-learned-from-primo-phase-2 2025-09-11T17:03:31+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/in-light-of-primo-and-collateral-studies-about-the-safety-tolerability-efficacy-dosing-and-combinatorial-studies-based-on-duvelisib-can-you-discuss-the-terzo-trial-design-and-what-we-expect-to-learn-in-r/r-ptcl-tfh 2025-09-11T17:04:37+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/in-light-of-the-unmet-need-for-improving-response-rates-in-relapsed/resistant-cases-of-persons-with-ptcl-tfh-how-did-your-group-identify-the-dual-delta-gamma-pi3k-inhibitor-duvelisib-for-managing-r/r-cases 2025-09-03T03:12:09+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/please-give-us-a-review-of-the-current-response-rates-for-treatment-options-deployed-in-ptcl-tfh-and-especially-how-biomarker-driven-taxonomization-of-ptcl-into-distinct-subtypes-is-guiding-approaches 2025-09-03T03:12:59+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/what-trial-based-evidence-did-you-and-your-colleagues-generate-beyond-the-primo-study-that-evaluated-the-efficacy-safety-and-dosing-of-duvelisib-a-dual-delta-gamma-pi3k-inhibitor-in-ptcl-tfh 2025-09-11T17:04:08+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/given-the-improved-clinical-outcomes-observed-in-the-primo-trial-how-did-these-results-and-specific-signals-translate-into-nccn-recommendations 2025-09-03T03:08:03+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/how-should-clinicians-approach-duvelisib-use-in-ptcl-tfh-regarding-dosing-monotherapy-vs-combination-and-its-role-as-a-bridging-agent-to-allogeneic-transplant 2025-09-11T17:05:28+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/can-you-provide-a-detailed-summary-of-what-biomarkers-have-been-canonized-and-should-be-employed-to-identify-the-ptcl-tfh-patient-subgroup 2025-09-11T17:01:30+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/can-you-explain-to-specialists-who-have-not-yet-protocolized-duvelisib-into-their-strategy-for-r/r-ptcl-tfh-exactly-in-whom-when-and-at-what-dose-you-incorporate-duvelisib-into-your-treatment-plan 2025-09-03T03:08:21+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/in-your-view-what-are-the-most-important-unmet-needs-in-clinical-trial-design-for-ptcl-tfh 2025-09-03T03:09:14+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/based-on-the-primo-phase-2-study-evaluating-duvelisib-in-ptcl-tfh-how-should-oncologists-managing-patients-with-this-variant-of-ptcl-tfh-think-about-deploying-this-dual-gamma-delta-pi3k-inhibitor-in-the-r/r-subgroup-afflicted-with-this-p 2025-09-03T02:58:33+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/can-you-discuss-what-the-current-post-chop-therapy-landscape-looks-like-for-persons-with-ptcl-tfh-in-particular-for-patients-who-have-relapsed-failed-and/or-are-resistant-to-chop 2025-09-03T03:11:57+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/what-s-your-rationale-for-duvelisib-dosing-in-1-bridging-to-allogeneic-transplant-2-achieving-cr-in-r/r-ptcl-tfh-and-3-palliative-care 2025-09-03T03:08:50+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/once-the-ptcl-tfh-subtype-is-confirmed-what-is-typically-the-treatment-roadmap-what-treatment-responses-can-be-expected-what-percentage-is-predicted-to-relapse-and/or-have-resistant-r/r-disease 2025-09-11T17:02:21+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/can-you-take-us-through-your-diagnostic-protocols-biomarker-panels-and-pathway-approaches-to-establish-the-presence-of-ptcl-tfh-and-your-considerations-in-those-patients-who-have-relapsed/resistant-ptcl-tfh 2025-09-03T02:58:45+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/at-what-point-with-ptcl-tfh-do-you-introduce-duvelisib-treatment-do-you-use-it-in-the-first-line-setting-or-do-you-currently-reserve-it-for-r/r-patients-and-as-a-bridge-for-allograft-stem-cell-transplantion 2025-09-03T03:09:27+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/can-you-discuss-the-challenges-of-classifying-subtypes-of-ptcl-especially-ptcl-tfh-and-how-to-optimize-biomarker-based-diagnosis-of-this-condition-to-ensure-actionable-and-precision-based-therapies-are-identified 2025-09-03T03:04:22+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/in-light-of-the-evidence-for-duvelisib-in-r/r-ptcl-tfh-as-well-as-its-use-for-bridging-to-allograft-bone-transplantation-what-can-specialists-draw-on-to-guide-their-use-of-duvelisib-centric-regiments-in-r/r-patients 2025-09-11T17:06:23+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/can-you-discuss-your-experience-with-duvelisib-in-persons-with-the-ptcl-tfh-subtype-and-what-range-of-response-rates-you-have-observed-as-well-as-your-deployment-of-duvelisib-as-bridge-therapy-for-patients-awaiting-allograft-stem-cell-tr 2025-09-03T03:10:49+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/professor-horwitz-can-you-please-give-us-a-general-introduction-to-the-subtype-specific-landscape-of-ptcl-with-a-focus-on-nodal-ptcl-tfh-t-follicular-helper-phenotype 2025-09-11T16:59:15+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/what-do-you-see-as-the-near-future-role-of-duvelisib-in-this-patient-subgroup-even-before-the-results-of-the-terzo-trial-are-reported 2025-09-03T03:09:02+0000 weekly 0.8 https://067527.iqanda-cme.com/videos/can-you-discuss-what-we-learned-from-the-primo-trial-that-focused-on-the-efficacy-actionable-outcome-signals-observed-with-duvelisib-in-this-trial-and-the-safety-of-the-dual-delta-gamma-pi3k-inhibitor-duvelisib 2025-09-03T02:59:00+0000 weekly 0.8 https://067527.iqanda-cme.com/courses/the-iqanda-ptcl-hematology-oncology-intelligence-zone-biomarker-direct-stratification-evolving-therapies-and-clinical-trials-for-relapsed/refractory-nodal-tfh-lymphoma 2026-02-02T23:33:48+0000 weekly 0.8